SWOG S1406: Vemurafenib in Combination With Irinotecan and Cetuximab in BRAF V600E Metastatic CRC

June 2-6, 2017; Chicago, Illinois
In this open-label phase II study, addition of vemurafenib associated with significantly improved PFS and clinical activity in BRAF V600E mCRC patients previously treated with systemic chemotherapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 245 KB
Released: June 12, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Final analysis from KEYNOTE-177 of first-line pembrolizumab vs chemotherapy in patients with MSI-H/dMMR metastatic CRC from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 17, 2021

Expert video on new and established therapies targeting HER2/HER3 in gastrointestinal cancers, from Clinical Care Options (CCO)

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Daniel Catenacci, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.5 Medical Knowledge MOC point(s) Released: May 27, 2021 Expired: May 26, 2022

In this slideset from Clinical Care Options (CCO), experts discuss their thoughts on the use of regorafenib and TAS-102 for colorectal cancer (CRC).

person default Joleen Hubbard, MD John L. Marshall, MD Released: April 29, 2021

Experts review key data in gastrointestinal cancers presented at ASCO GI 2021, as reported by Clinical Care Options (CCO)

Axel Grothey Headshot Axel Grothey, MD Manish A. Shah, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: March 10, 2021 Expired: March 9, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue